文献速递血栓与止血

艾曲泊帕治疗亚太、中东和土耳其慢性免疫性血小板减少症患者:CITE最终分析

Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE.
PubMed 文献 · Blood Adv · 2023-01-01

CITE是一项在亚太、中东和土耳其开展的前瞻性非干预研究,纳入231例接受艾曲泊帕常规治疗的成人慢性免疫性血小板减少症患者。中位治疗484.5天,用药依从性≥96.0%,基线中位血小板19.0×10³/μL升至第2个月≥50×10³/μL,FACIT-F评分从基线34.4改善至第18个月38.5,不良事件发生率50.9%。

要点

  • 231例患者中位艾曲泊帕治疗484.5天,按处方剂量依从性≥96.0%。
  • 中位首次血小板应答时间1.05个月,中位最长应答持续时间193天。
  • FACIT-F评分从基线均值34.4改善至第18个月38.5。

核心结论

  • 研究结果证实艾曲泊帕在常规实践中有效,真实世界中对处方剂量和饮食说明的依从性与当前推荐一致。

研究设计与样本

  • CITE为前瞻性非干预研究,纳入亚太、中东和土耳其接受常规临床治疗的成人慢性免疫性血小板减少症患者,共231例。
  • 数据收集时间为2017年5月至2020年12月,中位(范围)艾曲泊帕治疗持续时间为484.5(1-642)天。

主要发现

  • 基线中位血小板计数为19.0×10³/μL,第2个月升至≥50×10³/μL,此后多在70×10³/μL至100×10³/μL之间波动。
  • 中位首次血小板应答时间为1.05个月(95%CI:0.92-1.28),中位(四分位距)最长血小板应答持续时间为193(57-456)天。
  • FACIT-F评分从基线均值(标准差)34.4(12.1)改善至第18个月38.5(9.1)。
  • 不良事件发生率为50.9%(n=116),最常见为上呼吸道感染(8.3%)和头痛(6.6%)。
  • 自上次常规访视以来对处方艾曲泊帕剂量的依从性高,≥96.0%。

关键数值与推荐

  • 血小板应答定义为无挽救药物和脾切除情况下血小板计数≥50×10³/μL。
  • 不依从定义为漏服剂量次数和患者未遵循饮食说明的天数。
  • 生活质量采用慢性病治疗功能评估-疲劳(FACIT-F)问卷评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CITE was a prospective, noninterventional study in adult patients with chronic immune thrombocytopenia treated with eltrombopag under routine clinical care in Asia-Pacific, the Middle East, and Turkey. Data to assess eltrombopag usage, compliance, and outcomes were collected from May 2017 to December 2020. Platelet response was defined as platelet count ≥50 × 103/μL in the absence of rescue medications and splenectomy. Quality of life was evaluated using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Noncompliance was defined as the number of missed doses and number of days where the patient did not follow food instructions. A total of 231 patients were enrolled; the median (range) duration of eltrombopag treatment was 484.5 (1-642) days. Compliance to prescribed eltrombopag dose since the previous routine visit was high at ≥96.0%. Baseline median platelet count was 19.0 × 103/μL, which increased to ≥50 × 103/μL at month 2 and mostly fluctuated between 70 × 103/μL and 100 × 103/μL thereafter. The median time to first platelet response was 1.05 (95% confidence interval: 0.92-1.28) months, and the median (interquartile range) maximum duration of platelet response was 193 (57-456) days. FACIT-F scores improved from a mean (standard deviation) 34.4 (12.1) at baseline to 38.5 (9.1) at month 18. Adverse events occurred in 50.9% of patients (n = 116), the most common being upper respiratory tract infection (8.3%) and headache (6.6%). These findings confirmed the effectiveness of eltrombopag treatment in routine practice and reassured that real-world compliance to eltrombopag-prescribed doses and dietary instructions in Asia-Pacific, the Middle East, and Turkey were in line with current recommendations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wong RSM, Yavaşoğlu İ, Yassin MA, et al. Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE. Blood Adv. 2023. PMID: 36103340. doi:10.1182/bloodadvances.2022008287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。